Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Real-time Estimate Cboe BZX  -  09:40 2022-11-28 am EST
3.575 USD   -0.42%
04:26aADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology

09/22/2022 EST

ADC Therapeutics SA announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022. LOTIS-5 Initial Safety Run-In Results: LOTIS-5 is a Phase 3, randomized, open-label, two-part, two-arm, multicenter study of loncastuximab tesirine in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Twenty patients were enrolled in part 1 in a nonrandomized safety run-in.

In part 2, approximately 330 patients will be randomized 1:1 to receive Lonca-R or rituximab-gemcitabine-oxaliplatin (R-GemOx). The 20 patients in the safety run-in were a median age of 74.5 years (range 35-93) and received a median of 1 previous therapy (range 1-6). As of the February 28, 2022, data cutoff: The overall response rate by central review was 15/20 (75%).

A total of 8/20 (40%) and 7/20 (35%) patients attained complete response and partial response, respectively. The most common all-grade TEAEs, regardless of the relationship to the study treatment, were rash (5 [25%]), fatigue (4 [20%]), and increased gamma-glutamyl transferase (4 [20%]). The most common grade =3 TEAEs were increased gamma-glutamyl transferase (3 [15%]), increased alanine aminotransferase (2 [10%]), and neutropenia (2 [10%]).

These data will be presented in the following poster: Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL; Poster Number: ABCL-320; Details of ADC Therapeutics' other poster presentations: A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) (Encore data, first time as presentation); Poster Number: ABCL-272; Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (LOTIS-2); Poster Number: ABCL-316; Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Encore data, first time as presentation); Poster Number: ABCL-334; Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (Encore); Poster Number: HL-339. Details of ADC Therapeutics' oral presentation: Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (Encore); Date and Time: September 30, 5:48-5:58 p.m. CT; Location: Grand Ballroom G-L, 4th floor; Presenter: Alex Herrera, MD, City of Hope, Duarte, California, USA; Session XII: Hodgkin Lymphoma.


ę S&P Capital IQ 2022
All news about ADC THERAPEUTICS SA
04:26aADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targe..
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
11/08ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 196 M - -
Net income 2022 -159 M - -
Net cash 2022 309 M - -
P/E ratio 2022 -1,76x
Yield 2022 -
Capitalization 287 M 287 M -
EV / Sales 2022 -0,11x
EV / Sales 2023 0,80x
Nbr of Employees 312
Free-Float 46,9%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,59 $
Average target price 14,17 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Joseph S. Camardo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-82.23%287
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.58%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930